Skip to main content

Celldex Therapeutics, Inc. (CLDX) Stock Analysis

SellModerate Confidence

Healthcare · Biotechnology

Sell if holding. Engine safety override at $31.33: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum.

Celldex Therapeutics is a clinical-stage biopharmaceutical company focused on mast cell biology, with lead asset barzolvolimab (CDX-0159) in two global Phase 3 trials for chronic spontaneous urticaria enrolling ~1,939 patients, with topline data expected Q4 2026. The company has... Read more

$31.33+59.0% A.UpsideScore 5.2/10#84 of 157 Biotechnology
QualityF-score3 / 9FCF yield-5.13%
Stop $30.20Target $49.84(analyst − 13%)A.R:R 6.1:1
Analyst target$57.29+82.8%14 analysts
$49.84our TP
$31.33price
$57.29mean
$90

Sell if holding. Engine safety override at $31.33: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 5.2/10, moderate confidence.

Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news boost analyst 0.70, earnings proximity 81d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.

Val9.0Qual1.4Grw5.0Mom3.1Sent8.9Ins5.0Peer3.7Tech8.2Risk4.75.2OVERALL

Recent Developments — Celldex Therapeutics, Inc.

Latest news

Generated 2026-05-20T20:21:21Z.

Thesis

Rewards
Recent Analyst detected in news
Risks
Quality below floor (1.4 < 4.0)

Key Metrics

P/E (TTM)—
P/E (Fwd)-6.9
Mkt Cap$2.5B
EV/EBITDA-6.6
Profit Mgn0.0%
ROE-48.9%
Rev Growth-97.8%
Beta0.98
DividendNone
Rating analysts22

Quality Signals

Piotroski F3/9

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

4 floor-breakers·2 ceiling hits

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe
0.0
Roa
0.0
Gross Margin
0.0
Net Margin
0.0
Fcf Quality
0.0
Moat
3.2
Piotroski F
3.3
Current Ratio
5.0
Cash-burning: FCF -14598% of revenueNo competitive moatWeak Piotroski F-Score: 3/9Quality concerns

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Obv
1.0
Volume
2.9
Ma Position
4.0
Rsi
7.6
Uptrend pullback (RSI 39) - buy opportunityVolume distribution (falling OBV)Above 200-day MA

No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static

Earnings History
0.0
Surprise Avg
0.0
Earnings Timing
5.0
News Activity
5.0
Erm
6.5
Earnings concerns: 0B/4M

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Growth Rank
0.1
Quality Rank
2.6
Value Rank
5.0
GatesMomentum 3.1<4.5A.R:R 6.1 ≥ 1.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.70EARNINGS PROXIMITY 81d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Aggressive
RSI
39 · Neutral
↓ 20D MA↓ 50D MA↑ 200D MAGOLDEN CROSSSupport $31.13Resistance $35.79

Price Targets

$30
$50
A.Upside+59.1%
A.R:R6.1:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! Quality below floor (1.4 < 4.0)
! Momentum score 3.1/10 — below 4.5 minimum

Earnings

M
M
M
M
0/4 beats
Next Earnings2026-08-06 (81d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is CLDX stock a buy right now?

Sell if holding. Engine safety override at $31.33: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.2/10 and A.R:R 6.1:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 11%; Below-average business quality; Negative price momentum. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $30.20. Score 5.2/10, moderate confidence.

What is the CLDX stock price target?

Take-profit target: $49.84 (+59.0% upside). Prior stop was $30.20. Stop-loss: $30.20.

What are the risks of investing in CLDX?

Quality below floor (1.4 < 4.0).

Is CLDX overvalued or undervalued?

Celldex Therapeutics, Inc. trades at a P/E of N/A (forward -6.9). TrendMatrix value score: 9.0/10. Verdict: Sell.

What do analysts say about CLDX?

22 analysts cover CLDX with a consensus score of 4.2/5. Average price target: $57.

What does Celldex Therapeutics, Inc. do?Celldex Therapeutics is a clinical-stage biopharmaceutical company focused on mast cell biology, with lead asset...

Celldex Therapeutics is a clinical-stage biopharmaceutical company focused on mast cell biology, with lead asset barzolvolimab (CDX-0159) in two global Phase 3 trials for chronic spontaneous urticaria enrolling ~1,939 patients, with topline data expected Q4 2026. The company has accumulated a $1.8 billion operating deficit and no product revenue.

Related stocks: AUPH (Aurinia Pharmaceuticals Inc) · INCY (Incyte Corporation) · HALO (Halozyme Therapeutics, Inc.) · INVA (Innoviva, Inc.) · HRMY (Harmony Biosciences Holdings, I)